In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1258-1264

  Lepak, Alexander J ^a   Marchillo, Karen ^c   Craig, William A ^d   Andes, David R ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

LANTIBIOTIC; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; ANIMAL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; MICE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THIGH;

EID: 84921921878     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04444-14     Document Type: Article

References (47)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
2. Bassetti M, Merelli M, Temperoni C, Astilean A. 2013. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12:22. http: //dx.doi.org/10.1186/1476-0711-12-22.
3. Infectious Diseases Society of America. 2010. The 10 - '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081-1083. http://dx.doi.org/10.1086/652237.
4. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Jr, Infectious Diseases Society of America. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164. http://dx.doi.org/10.1086/524891.
5. Infectious Diseases Society of America (IDSA), Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN. 2011. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52 (Suppl 5): S397-S428. http: //dx.doi.org/10.1093/cid/cir153.
6. Brumfitt W, Salton MR, Hamilton-Miller JM. 2002. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrob Chemother 50:731-734. http://dx.doi.org/10 .1093/jac/dkf190.
7. Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi D, Marinelli F, Selva E, Parenti F. 2008. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem Biol 15:22-31. http://dx .doi.org/10.1016/j.chembiol.2007.11.009.
8. Breukink E, de Kruijff B. 2006. Lipid II as a target for antibiotics. Nat Rev Drug Discov 5:321-332. http://dx.doi.org/10.1038/nrd2004.
9. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl HG, de Kruijff B. 1999. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286:2361-2364. http://dx.doi.org/10.1126 /science.286.5448.2361.
10. Brötz H, Josten M, Wiedemann I, Schneider U, Gotz F, Bierbaum G, Sahl HG. 1998. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 30:317-327. http://dx.doi.org/10.1046/j.1365-2958.1998.01065.x.
11. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG. 2001. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276:1772-1779. http://dx.doi.org/10.1074/jbc.M006770200.
12. Münch D, Muller A, Schneider T, Kohl B, Wenzel M, Bandow JE, Maffioli S, Sosio M, Donadio S, Wimmer R, Sahl HG. 2014. The lantibiotic NAI-107 binds to bactoprenol-bound cell wall precursors and impairs membrane functions. J Biol Chem 289:12063-12076. http://dx .doi.org/10.1074/jbc.M113.537449.
13. Castiglione F, Cavaletti L, Losi D, Lazzarini A, Carrano L, Feroggio M, Ciciliato I, Corti E, Candiani G, Marinelli F, Selva E. 2007. A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp. Biochemistry 46:5884-5895. http: //dx.doi.org/10.1021/bi700131x.
14. Cotter PD, Hill C, Ross RP. 2005. Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci 6:61-75. http://dx .doi.org/10.2174/1389203053027584.
15. th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
16. National Research Council Committee on the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources and Commission on Life Sciences. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
17. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicil-lin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 42:2375-2379.
18. Fauci AS, Morens DM. 2012. The perpetual challenge of infectious diseases. N Engl J Med 366:454-461. http://dx.doi.org/10.1056/NEJMra1108296.
19. Morens DM, Fauci AS. 2012. Emerging infectious diseases in 2012: 20 years after the Institute of Medicine report. mBio 3(6):e00494-12. http: //dx.doi.org/10.1128/mBio.00494-12.
20. Morens DM, Folkers GK, Fauci AS. 2004. The challenge of emerging and reemerging infectious diseases. Nature 430:242-249. http://dx.doi.org/10 .1038/nature02759.
21. Taubes G. 2008. The bacteria fight back. Science 321:356-361. http://dx .doi.org/10.1126/science.321.5887.356.
22. Buckingham SC, McDougal LK, Cathey LD, Comeaux K, Craig AS, Fridkin SK, Tenover FC. 2004. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee children's hospital. Pediatr Infect Dis J 23:619-624. http://dx.doi.org/10.1097 /01.inf.0000131981.67342.c4.
23. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. 2009. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 301:727-736. http://dx.doi.org/10.1001/jama.2009.153.
24. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. 2013. Antimicrobialresistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1-14. http://dx.doi.org/10.1086/668770.
25. Talbot GH. 2008. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther 6:39-49. http://dx.doi.org/10.1586/14787210 .6.1.39.
26. Talbot GH, Bradley J, Edwards JE, Jr, Gilbert D, Scheld M, Bartlett JG, Antimicrobial Availability Task Force of the Infectious Diseases Society of America. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42:657-668. http://dx.doi.org /10.1086/499819.
27. Spellberg B. 2008. Antibiotic resistance and antibiotic development. Lancet Infect Dis 8:211-212. http://dx.doi.org/10.1016/S1473 -3099(08)70048-3.
28. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N Engl J Med 368:299-302. http://dx.doi.org/10.1056 /NEJMp1215093.
29. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE, Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38:1279-1286. http://dx.doi.org/10.1086/420937.
30. Nathan C. 2004. Antibiotics at the crossroads. Nature 431:899-902. http: //dx.doi.org/10.1038/431899a.
31. Klevens RM, Edwards JR, Richards CL, Jr, Horan TC, Gaynes RP, Pollock DA, Cardo DM. 2007. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 122:160-166.
32. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core Surveillance (ABCs) MRSA Investigators. 2007. Invasive methicil-lin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. http://dx.doi.org/10.1001/jama.298.15.1763.
33. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
34. Rice LB. 2012. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc 87:198-208. http://dx.doi.org/10.1016/j.mayocp.2011.12.003.
35. Rodvold KA, McConeghy KW. 2014. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 58(Suppl 1):S20-S27. http://dx.doi.org/10.1093/cid/cit614.
36. Rubinstein E, Keynan Y. 2013. Vancomycin-resistant enterococci. Crit Care Clin 29:841-852. http://dx.doi.org/10.1016/j.ccc.2013.06.006.
37. Calfee DP. 2012. Methicillin-resistant Staphylococcus aureus and van-comycin-resistant enterococci, and other Gram-positives in healthcare. Curr Opin Infect Dis 25:385-394. http://dx.doi.org/10.1097/QCO .0b013e3283553441.
38. Stryjewski ME, Corey GR. 2014. Methicillin-resistant Staphylococcus aureus: an evolving pathogen. Clin Infect Dis 58(Suppl 1):S10-S19. http://dx .doi.org/10.1093/cid/cit613.
39. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7:629-641. http://dx.doi.org /10.1038/nrmicro2200.
40. Dawson MJ, Scott RW. 2012. New horizons for host defense peptides and lantibiotics. Curr Opin Pharmacol 12:545-550. http://dx.doi.org/10.1016 /j.coph.2012.06.006.
41. van Heusden HE, de Kruijff B, Breukink E. 2002. Lipid II induces a transmembrane orientation of the pore-forming peptide lantibiotic nisin. Biochemistry 41:12171-12178. http://dx.doi.org/10.1021/bi026090x.
42. Jabés D, Brunati C, Candiani G, Riva S, Romano G, Donadio S. 2011. Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens. Antimicrob Agents Chemother 55: 1671-1676. http://dx.doi.org/10.1128 /AAC.01288-10.
43. Andes D, Craig WA. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 50:1376-1383. http://dx.doi.org/10.1128/AAC.50.4 .1376-1383.2006.
44. Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48:63-68. http://dx.doi .org/10.1128/AAC.48.1.63-68.2004.
45. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trim-ethoprim-sulfamethoxazole, and vancomycin against communityassociated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 52:2156-2162. http://dx.doi.org/10.1128/AAC.01046-07.
46. Lee DG, Murakami Y, Andes DR, Craig WA. 2013. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 105 and 107 CFU injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother 57:1434-1441. http://dx.doi.org/10.1128/AAC.00362-12.
47. Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR. 2012. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 56:5916-5922. http: //dx.doi.org/10.1128/AAC.01303-12.